Alpha Paradigm Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Alpha Paradigm Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,710	Closed	-$292K	–	641
2022 Q3	$292K	Sell	4,710 -17,617	-79%	-$1.23M	0.13%	245
2022 Q2	$1.78M	Buy	22,327 +15,066	+207%	+$1.43M	0.74%	16
2022 Q1	$764K	Sell	7,261 -3,918	-35%	-$382K	0.3%	92
2021 Q4	$1.21M	Buy	11,179 +3,947	+55%	+$431K	0.48%	36
2021 Q3	$792K	Buy	7,232 +3,580	+98%	+$372K	0.32%	96
2021 Q2	$342K	Hold	3,652	–	–	0.13%	270
2021 Q1	$336K	Sell	3,652 -11,377	-76%	-$960K	0.13%	235
2020 Q4	$1.1M	Buy	+15,029	New	+$1.12M	0.38%	70

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alpha Paradigm Partners's HZNP Position: Q4 2022 in Review

Alpha Paradigm Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 4,710 shares — an estimated $292K sold.

Alpha Paradigm Partners first reported a position in HZNP in Q4 2020 and held it in 8 quarters. The position peaked at $1.78M in Q2 2022. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Alpha Paradigm Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Alpha Paradigm Partners sold 4,710 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $292K.
Alpha Paradigm Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 8 quarters.
Alpha Paradigm Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.78M in Q2 2022.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Alpha Paradigm Partners's 13F filing for Q4 2022, filed 13 Feb 2023.